GAINESVILLE, Fla.--(BUSINESS WIRE)--
Exactech (EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that 16 presentations featuring new scientific and clinical research in the areas of shoulder and knee arthroplasty, orthobiologics and computer-assisted surgery were presented at the 2017 Orthopaedic Research Society (ORS) annual meeting, March 19-22 in San Diego, Calif.
“As a company with a strong scientific foundation, we were pleased to have a wide-ranging scope of research represented,” said Exactech Co-founder and Executive Vice President of Research and Development Gary Miller, PhD. “These studies will provide information that will help further our company’s commitment to improving patient outcomes with proven advancements.”
Multinational patient outcomes data drawn from more than a decade of active clinical activity provided engineering and development, clinical research teams and worldwide clinical collaborators robust information to assess the evolving performance of Exactech products.
Shoulder discoveries included outcomes reports and comparisons based on humeral and glenoid implant type and such variables as gender and age of the patient. In the use of computer assisted surgical navigation, precision and accuracy, surgeon experience and learning curve parameters were reported for various groups of knee arthroplasty patients. A knee study revealed geographic differences that could help define effective knee femoral component designs. Finally, scientists studied viability of human chondrocytes in cryopreserved cartilage fragments that could determine successful clinical application.
Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.
A current investment profile on Exactech (EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.